shutterstock_1572740566_nitpicker
nitpicker / Shutterstock.com
13 April 2021Big PharmaRory O'Neill

Sanofi and C4X in $493m licensing deal

UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million ($493 million), which will see the French pharmaceutical company develop anti-inflammatory therapies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
1 April 2021   Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi
Biotechnology
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Americas
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.

More on this story

Medtech
1 April 2021   Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi
Biotechnology
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Americas
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.

More on this story

Medtech
1 April 2021   Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi
Biotechnology
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Americas
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.